Scholar Rock Q2 2022 Earnings Report
Key Takeaways
Scholar Rock reported a net loss of $44.0 million for the second quarter of 2022. Enrollment continues to advance in the pivotal Phase 3 SAPPHIRE trial for apitegromab in SMA. The company's cash, cash equivalents, and marketable securities were approximately $371 million as of June 30, 2022.
Positive 24-month data from ongoing Phase 2 TOPAZ trial extension supports potential benefit of apitegromab for patients with Types 2 and 3 Spinal Muscular Atrophy (SMA).
Actively enrolling in pivotal Phase 3 SAPPHIRE clinical trial for apitegromab
Discovery pipeline advancements made for LTBP-TGFβ1 target to treat a wide range of fibrotic diseases
Significantly strengthened balance sheet with the completion of $205 million registered direct offering
Scholar Rock
Scholar Rock
Forward Guidance
Scholar Rock expects that its cash, cash equivalents, and marketable securities of approximately $371 million as of June 30, 2022, will fund the Company’s anticipated operating and capital expenditure requirements into 2025.